Document is current
Any future updates will be listed below
-
Authors
Nederlof, Iris
De Bortoli, Davide
Bareche, Yacine
Nguyen, Bastien
de Maaker, Michiel
Hooijer, Gerrit K. J.
Buisseret, Laurence
Kok, Marleen
Smid, Marcel
Van den Eynden, Gert G. G. M.
Brinkman, Arie B.
Hudecek, Jan
Koster, Jan
Sotiriou, Christos
Larsimont, Denis
Martens, John W. M.
van de Vijver, Marc J.
Horlings, Hugo M.
Salgado, Roberto
Biganzoli, Elia
Desmedt, Christine https://orcid.org/0000-0002-5223-5579
-
Funding
Funding for this research was provided by:
Amis de l'Institut Bordet (/)
Fondation Cancer (/)
KWF Kankerbestrijding (grant 10510)
Fonds De La Recherche Scientifique - FNRS (Télévie)
Associazione Italiana per la Ricerca sul Cancro (/)
Breast Cancer Research Foundation (17-194)
- License Information
-
More Information
Article History
Received: 5 August 2019
Accepted: 16 December 2019
First Online: 26 December 2019
Ethics approval and consent to participate
: This ICGC Breast Cancer dataset is hosted by the ICGC and deposited at . Data access was granted by the International Cancer Genome Consortium (ICGC).
: Not applicable
: J.H. is the owner of Slide Score B.V. L.B. reports participating fee paid by BMS for its R&D day. MK reports funding to the institute from BMS, Roche and an advisory role for BMS, outside the submitted work. CS reports an advisory role for Astellas Pharma, Cepheid, Vertex, Puma Biotechnology, Seattle Genetics, and Amgen, as well as travel funds from Roche and Genentech, and intellectual property including epigenetic portraits of human breast cancer (PCT/EP2012/050836, WO2012/098215); a companion diagnostic for CDK4/CDK6 inhibitory drugs that is based on CDK4 phosphorylation, which patient to be treated and how (PCT/EP2017/061780) Speakers’ Bureau: Eisai, Prime Oncology, Teva, Foundation Medicine. M.J.vd. V reports research funding from MSD research and an advisory role for Hoffmann-La Roche. R.S. reports research funding from Merck and Roche, as well as travel funds from Astra Zeneca, Roche, Merck, and BMS and an advisory role for BMS and Roche, outside the scope of this work. C.D. reports speakers fee paid directly to the institution from Roche Diagnostics. The other authors declare that they have no competing interests.
